• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . The Emerging SARS-CoV-2 Papain-like Protease: Its Relationship with Recent Coronavirus Epidemics

tetano

Editor, Senior Moderator
J Med Virol


. 2020 Sep 9.
doi: 10.1002/jmv.26497. Online ahead of print.
The Emerging SARS-CoV-2 Papain-like Protease: Its Relationship with Recent Coronavirus Epidemics


Mahmoud Kandeel[SUP] 1 2 [/SUP], Yukio Kitade[SUP] 3 4 [/SUP], Mahmoud Fayez[SUP] 5 6 [/SUP], Katharigata N Venugopala[SUP] 7 8 [/SUP], Abdelazim Ibrahim[SUP] 9 10 [/SUP]



Affiliations

Abstract

Background: The papain-like protease (PL[SUP]pro[/SUP] ) is an important enzyme for coronavirus polyprotein processing, as well as for virus-host immune suppression. Previous studies reveal that a molecular analysis of PL[SUP]pro[/SUP] indicates the catalytic activity of viral PL[SUP]pro[/SUP] and its interactions with ubiquitin.
Methods: By using sequence comparisons, molecular models and protein-protein interaction maps, PL[SUP]pro[/SUP] was compared in the three recorded fatal CoV epidemics, which involved SARS-CoV-2, SARS-CoV and MERS-CoV.
Results: The pairwise sequence comparison of SARS-CoV-2 PL[SUP]pro[/SUP] indicated similarity percentages of 82.59% and 30.06% with SARS-CoV PL[SUP]pro[/SUP] and MERS-CoV PL[SUP]pro[/SUP] , respectively. In comparison with SARS-CoV PL[SUP]pro[/SUP] , in SARS-CoV-2, the PL[SUP]pro[/SUP] had a conserved catalytic triad of C111, H278 and D293, with a slightly lower number of polar interface residues and of hydrogen bonds, a higher number of buried interface sizes and a lower number of residues that interact with ubiquitin and PL[SUP]pro[/SUP] . These features might contribute to a similar or slightly lower level of deubiquitinating activity in SARS-CoV-2 PL[SUP]pro[/SUP] . It was, however, a much higher level compared to MERS-CoV, which contained amino acid mutations and a low number of polar interfaces.
Conclusion: SARS-CoV-2 PL[SUP]pro[/SUP] and SARS-CoV PL[SUP]pro[/SUP] showed almost the same catalytic site profiles, interface area compositions and polarities, suggesting a general similarity in deubiquitination activity. Compared with MERS-CoV, SARS-CoV-2 had a higher potential for binding interactions with ubiquitin. These estimated parameters contribute to the knowledge gap in understanding how the new virus interacts with the immune system. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; SARS-CoV-2; innate immunity; molecular modeling; papain-like protease.
 
Back
Top Bottom